NCT03687333View on ClinicalTrials.gov

Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Glycogen Storage Disease Type II
Interventions
DRUG

ALGLUCOSIDASE ALFA (MYOZYME)

"Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion"

Trial Locations (1)

Unknown

Investigational site number, Shanghai

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT03687333 - Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment | Biotech Hunter | Biotech Hunter